Aberdeen Group
RARE icon

Aberdeen Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Aberdeen Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-38,499
Closed -$807K – 967
2026
Q1 		$807K Sell
38,499
-1,431,452
-97% -$32.2M ﹤0.01% 846
2025
Q4 		$33.8M Buy
1,469,951
+496,295
+51% +$16.3M 0.05% 292
2025
Q3 		$29.3M Buy
973,656
+472,600
+94% +$14.2M 0.05% 323
2025
Q2 		$18.2M Buy
501,056
+22,152
+5% +$799K 0.03% 440
2025
Q1 		$17.3M Buy
478,904
+161,779
+51% +$6.73M 0.03% 432
2024
Q4 		$13.3M Buy
317,125
+63,821
+25% +$3.17M 0.03% 450
2024
Q3 		$14.1M Sell
253,304
-31,441
-11% -$1.6M 0.03% 456
2024
Q2 		$11.7M Buy
284,745
+143,628
+102% +$6.13M 0.02% 483
2024
Q1 		$6.59M Hold
141,117
– – 0.01% 621
2023
Q4 		$6.75M Buy
+141,117
New +$5.47M 0.01% 620

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Aberdeen Group's RARE Position: Q2 2026 in Review

Aberdeen Group sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 38,499 shares — an estimated $807K sold.

Aberdeen Group first reported a position in RARE in Q4 2023 and held it in 10 quarters. The position peaked at $33.8M in Q4 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Aberdeen Group reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Aberdeen Group sold 38,499 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $807K.
  • Aberdeen Group first reported a position in Ultragenyx Pharmaceutical in Q4 2023 and held it in 10 quarters.
  • Aberdeen Group's Ultragenyx Pharmaceutical position peaked at $33.8M in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.